Apolipoprotein B measurement: need for standardization

American Association of Clinical Endocrinologists and American College of Endocrinology guidelines for management of dyslipidemia and prevention of cardiovascular disease

Jellinger, P. S., Handelsman, Y., Rosenblit, P. D., Bloomgarden, Z. T., Fonseca, V. A., Garber, A. J., Grunberger, G., Guerin, C. K., Bell, D. S. H., Mechanick, J. I., et al. (2017) · Endocrine Practice · doi:10.4158/ep171764.appgl · Cited by 1,094 · see citing works

International Federation of Clinical Chemistry standardization project for measurements of apolipoproteins A-I and B. III. Comparability of apolipoprotein A-I values by use of international reference material

Marcovina, S. M., Albers, J. J., Henderson, L. O., & Hannon, W. H. (1993) · Clinical Chemistry · doi:10.1093/clinchem/39.5.773 · Cited by 342 · see citing works

International federation of clinical Chemistry standardization project for measurements of apolipoproteins A-I and B. IV. Comparability of apolipoprotein B values by use of international reference material

Marcovina, S. M., Albers, J. J., Kennedy, H., Mei, J. V., Henderson, L. O., & Hannon, W. H. (1994) · Clinical Chemistry · doi:10.1093/clinchem/40.4.586 · Cited by 243 · see citing works

International Federation of Clinical Chemistry standardization project for measurements of apolipoproteins A-I and B

Marcovina, S. M., Albers, J. J., Dati, F., Ledue, T. B., & Ritchie, R. F. (1991) · Clinical Chemistry · doi:10.1093/clinchem/37.10.1676 · Cited by 228 · see citing works

Some considerations of methodology and standardization of apolipoprotein A-I immunoassays.

Steinberg, K., Cooper, G. R., GRAISER, S. R., & Rosseneu, M. (1983) · Clinical Chemistry · doi:10.1093/clinchem/29.3.415 · Cited by 149 · see citing works

Differential response of cholesterol and particle measures of atherogenic lipoproteins to LDL-lowering therapy: implications for clinical practice

Sniderman, A. D. (2008) · Journal of clinical lipidology · doi:10.1016/j.jacl.2007.12.006 · Cited by 116 · see citing works

Lipolysis Produces Changes in the Immunoreactivity and Cell Reactivity of Very Low Density Lipoproteins

Schonfeld, G., Patsch, W., Pfleger, B. A., Witztum, J. L., & Weidman, S. W. (1979) · Journal of Clinical Investigation · doi:10.1172/jci109584 · Cited by 115 · see citing works

International Federation of Clinical Chemistry Standardization Project for Measurements of Apolipoproteins A-I and B. II. Evaluation and Selection of Candidate Reference Materials

Albers, J. J., Marcovina, S. M., & Kennedy, H. (1992) · Clinical Chemistry · doi:10.1093/clinchem/38.5.658 · Cited by 103 · see citing works

Some considerations of methodology and standardization of apolipoprotein B immunoassays.

Rosseneu, M., VERCAEMST, R., Steinberg, K., & Cooper, G. R. (1983) · Clinical Chemistry · doi:10.1093/clinchem/29.3.427 · Cited by 84 · see citing works

Effect of moderate hypertriglyceridemia on the relation of plasma total and LDL apo B levels

Sniderman, A. D., Vu, H., & Cianflone, K. (1991) · Atherosclerosis · doi:10.1016/0021-9150(91)90050-d · Cited by 81 · see citing works

Immunoquantification of total apolipoprotein B in serum by nephelometry: influence of lipase treatment and detergents.

DaCol, P., & Kostner, G. M. (1983) · Clinical Chemistry · doi:10.1093/clinchem/29.6.1045 · Cited by 39 · see citing works

A comparison of three apolipoprotein B methods and their associations with incident coronary heart disease risk over a 12-year follow-up period: the Multi-Ethnic Study of Atherosclerosis

Cao, J., Steffen, B. T., Guan, W., Remaley, A. T., McConnell, J. P., Palamalai, V., & Tsai, M. Y. (2018) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2017.12.013 · Cited by 31 · see citing works

Effect of plasma triglyceride concentrations on the accuracy of immunoturbidimetric assays of apolipoprotein B

Walmsley, T. A., Grant, S., & George, P. M. (1991) · Clinical Chemistry · doi:10.1093/clinchem/37.5.748 · Cited by 14 · see citing works

Apolipoprotein B and Cardiovascular Disease: Biomarker and Potential Therapeutic Target

Behbodikhah, J., Ahmed, S., Elyasi, A., Kasselman, L. J., Leon, J. D., Glass, A. D., & Reiss, A. B. (2021) · Metabolites · doi:10.3390/metabo11100690 · Cited by 284 · see citing works

Quantifying atherogenic lipoproteins for lipid-lowering strategies: Consensus-based recommendations from EAS and EFLM

Nordestgaard, B. G., Langlois, M. R., Langsted, A., Chapman, M. J., Aakre, K. M., Baum, H., Borén, J., Bruckert, E., Catapano, A., Cobbaert, C., et al. (2020) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2019.12.005 · Cited by 240 · see citing works

Quantifying atherogenic lipoproteins for lipid-lowering strategies: consensus-based recommendations from EAS and EFLM

Langlois, M. R., Nordestgaard, B. G., Langsted, A., Chapman, M. J., Aakre, K. M., Baum, H., Borén, J., Bruckert, E., Catapano, A., Cobbaert, C., et al. (2020) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm-2019-1253 · Cited by 211 · see citing works

Lipid measurements in the management of cardiovascular diseases: Practical recommendations a scientific statement from the national lipid association writing group

Wilson, P. W. F., Jacobson, T. A., Martin, S. S., Jackson, E. J., Le, N., Davidson, M. H., Vesper, H. W., Frikke‐Schmidt, R., Ballantyne, C. M., & Remaley, A. T. (2021) · Journal of clinical lipidology · doi:10.1016/j.jacl.2021.09.046 · Cited by 134 · see citing works

The use of blood biomarkers in precision medicine for the primary prevention of atherosclerotic cardiovascular disease: a review

Sweeney, T. E., Quispe, R., Das, T. M., Juraschek, S. P., Martin, S. S., & Michos, E. D. (2021) · Expert Review of Precision Medicine and Drug Development · doi:10.1080/23808993.2021.1930531 · Cited by 23 · see citing works

Quantifying atherogenic lipoproteins for lipid-lowering strategies: consensus-based recommendations from EAS and EFLM

Langlois, M. R., Nordestgaard, B. G., Langsted, A., Chapman, M. J., Aakre, K. M., Baum, H. H. E., Borén, J., Bruckert, É., Catapano, A. L., Cobbaert, C. M., et al. (2021) · Laboratory Service · doi:10.17116/labs20211001145 · Cited by 13 · see citing works

Did the ACC/AHA/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA cholesterol guidelines get apoB right?

Sniderman, A. D. (2019) · Journal of clinical lipidology · doi:10.1016/j.jacl.2019.05.010 · Cited by 12 · see citing works

Precision medicine in secondary prevention of ischemic stroke: how may blood-based biomarkers help in clinical routine? An expert opinion

Bicciato, G., Arnold, M., Gebhardt, A., & Mira, K. (2021) · Current Opinion in Neurology · doi:10.1097/wco.0000000000001011 · Cited by 11 · see citing works

The Hepatic Fate of Vitamin E

Schmölz, L., Schubert, M., Kluge, S., Birringer, M., Wallert, M., & Stefan Lorkowski, A. (2018) · InTech eBooks · doi:10.5772/intechopen.79445 · Cited by 9 · see citing works

Vitamin E in Health and Disease

Packer, L. (2023) · CRC Press eBooks · doi:10.1201/9781003418160 · Cited by 7 · see citing works

Biochemical risk factors of atherosclerotic cardiovascular disease: from a narrow and controversial approach to an integral approach and precision medicine

van der Laarse, A., & Cobbaert, C. M. (2021) · Expert Review of Cardiovascular Therapy · doi:10.1080/14779072.2021.2022475 · Cited by 3 · see citing works

A failure of standardization or a failure of the process of standardization

Sniderman, A. D., & McQueen, M. (2018) · Journal of clinical lipidology · doi:10.1016/j.jacl.2018.05.009 · Cited by 3 · see citing works

Advanced Lipid Testing

Saeed, A., Nambi, V., & Jones, P. H. (2018) · Elsevier eBooks · doi:10.1016/b978-0-323-54835-9.00005-3 · Cited by 1 · see citing works

Apolipoprotein B in Primary Prevention: Ready for Time Prime?

Quispe, R., Varghese, B. T., & Martin, S. S. (2022) · Contemporary cardiology · doi:10.1007/978-3-030-98824-1_18

Apolipoprotein B at the core: another step forward

Pirillo, A., & Catapano, A. L. (2025) · European Heart Journal · doi:10.1093/eurheartj/ehaf572 · Cited by 2 · see citing works

Beyond LDL-C: The Clinical Mandate for ApoB in Contemporary Lipid Management

Sheets, A. (2026) · Digital Showcase Research, Scholarship, & Creative Works (University of Lynchburg)

Apolipoprotein B compared with low-density lipoprotein cholesterol in the atherosclerotic cardiovascular diseases risk assessment

Galimberti, F., Casula, M., & Olmastroni, E. (2023) · Pharmacological Research · doi:10.1016/j.phrs.2023.106873 · Cited by 63 · see citing works

How, when, and why to use apolipoprotein B in clinical practice

Sniderman, A. D. (2002) · The American Journal of Cardiology · doi:10.1016/s0002-9149(02)02633-4 · Cited by 66 · see citing works

Apolipoprotein B and Cardiovascular Disease Risk: Position Statement from the AACC Lipoproteins and Vascular Diseases Division Working Group on Best Practices

Contois, J. H., McConnell, J. P., Sethi, A. A., Csako, G., Devaraj, S., Hoefner, D. M., & Warnick, G. R. (2009) · Clinical Chemistry · doi:10.1373/clinchem.2008.118356 · Cited by 326 · see citing works